Fukuyuan Pharmaceuticals: Subsidiary Receives Approval Notification of Supplementary Application for Salicylic Acid Phenol Plaster Drug.

Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has obtained the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for "Salicylic Acid Phenol Plaster". The marketing authorization holder of this drug has been changed from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. This drug is mainly used for corns, and another 16 companies have obtained marketing approval. The sales of Salicylic Acid Phenol Plaster in China's three major terminal markets and six major markets are estimated to be approximately 68.92 million yuan in 2024. Fuyuan Pharmaceutical Co., Ltd. has become the marketing authorization holder of the aforementioned drug, further enriching the company's product line. However, due to uncertain factors such as national policies and market environment, there may be sales performance that does not meet expectations in the future for this drug.